These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10192452)

  • 1. Red cell deformability in oral contraceptive pill users with sickle cell anaemia.
    Yoong WC; Tuck SM; Yardumian A
    Br J Haematol; 1999 Mar; 104(4):868-70. PubMed ID: 10192452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of ovarian steroids on sickle cell deformability.
    Yoong WC; Tuck SM; Yardumian A
    Clin Lab Haematol; 1998 Jun; 20(3):151-4. PubMed ID: 9681229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study.
    Iversen L; Fielding S; Lidegaard Ø; Mørch LS; Skovlund CW; Hannaford PC
    BMJ; 2018 Sep; 362():k3609. PubMed ID: 30257920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markers of platelet activation, thrombin generation and fibrinolysis in women with sickle cell disease: effects of differing forms of hormonal contraception.
    Yoong WC; Tuck SM; Pasi KJ; Owens D; Perry DJ
    Eur J Haematol; 2003 May; 70(5):310-4. PubMed ID: 12694167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contraceptive Steroids, age, and the cardiovascular system.
    Plunkett ER
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):747-51. PubMed ID: 7065055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contraception for individuals with sickle cell disease: a systematic review of the literature.
    Haddad LB; Curtis KM; Legardy-Williams JK; Cwiak C; Jamieson DJ
    Contraception; 2012 Jun; 85(6):527-37. PubMed ID: 22152587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease.
    Gaspard UJ; Lefebvre PJ
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):334-43. PubMed ID: 2196805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progestogens in cardiovascular diseases: an introduction to the epidemiologic data.
    Mann JI
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):752-7. PubMed ID: 7065056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception.
    Bentzen JG; Forman JL; Pinborg A; Lidegaard Ø; Larsen EC; Friis-Hansen L; Johannsen TH; Nyboe Andersen A
    Reprod Biomed Online; 2012 Dec; 25(6):612-9. PubMed ID: 23069740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in hormonal contraception.
    Erkkola R
    Curr Opin Obstet Gynecol; 2007 Dec; 19(6):547-53. PubMed ID: 18007132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives.
    Shulman LP
    Am J Obstet Gynecol; 2011 Oct; 205(4 Suppl):S9-13. PubMed ID: 21961825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sexuological impact of hormonal contraceptives based on their route of administration.
    Guida M; Di Carlo C; Troisi J; Gallo A; Cibarelli F; Martini E; Tiranini L; Nappi RE
    Gynecol Endocrinol; 2017 Mar; 33(3):218-222. PubMed ID: 27908210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Customization of hormonal contraception].
    DE Leo V; Cianci A; DI Carlo C; Cappelli V; Fruzzetti F
    Minerva Ginecol; 2018 Feb; 70(1):1-26. PubMed ID: 29347814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contraceptive practices in women with sickle-cell disease.
    Carvalho NS; Braga JP; Barbieri M; Torloni MR; Figueiredo MS; Guazzelli CA
    J Obstet Gynaecol; 2017 Jan; 37(1):74-77. PubMed ID: 27924667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular effects and progestins in oral contraceptives.
    Wynn V
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):718. PubMed ID: 7065052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral oestrogen-progestagen contraceptives, menopausal treatment, and cancer.
    Shapiro S
    Lancet Oncol; 2005 Oct; 6(10):736; author reply 737. PubMed ID: 16198976
    [No Abstract]   [Full Text] [Related]  

  • 18. Risks and mechanisms of cardiovascular events in users of oral contraceptives.
    Meade TW
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1646-52. PubMed ID: 3287935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cancer of the breast. Influence of hormonal contraception].
    Gorins A
    Presse Med; 1984 May; 13(19):1207-10. PubMed ID: 6232568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progestin-only pills for contraception.
    Grimes DA; Lopez LM; O'Brien PA; Raymond EG
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007541. PubMed ID: 20091638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.